Thallion Pharmaceuticals Inc.
| Article | Date | Source |
|---|
| Thallion Announces Sale of its Stake in Caprion Proteomics | July 19, 2012 | Marketwire - Pharma and Biotech |
| Thallion and LFB Report Positive Top-Line Results from the Phase II SHIGATEC Trial at 'VTEC 2012' | May 09, 2012 | Marketwire - Pharma and Biotech |
| Thallion annonce ses résultats pour le premier trimestre 2012 | April 24, 2012 | Marketwire - Pharma and Biotech |
| Thallion Announces 2012 First Quarter Results and Provides Shigamabs Update | April 24, 2012 | Marketwire - Pharma and Biotech |
| Thallion annonce ses résultats de fin d'exercice 2011 | February 22, 2012 | Marketwire - Pharma and Biotech |
| Thallion Announces 2011 Year End Results | February 22, 2012 | Marketwire - Pharma and Biotech |
| Thallion and LFB Complete Patient Enrollment of Phase II SHIGATEC Trial | January 09, 2012 | Marketwire - Pharma and Biotech |
| Thallion Pharmaceuticals Inc.: Blinded Results From Low Dose Cohort of Phase II SHIGATEC Trial Presented at IDSA Annual Meeting | October 24, 2011 | Marketwire - Pharma and Biotech |
| Thallion Announces 2011 Third Quarter Results | October 11, 2011 | Marketwire - Pharma and Biotech |
| Thallion Resuming Patient Recruitment in Phase II SHIGATEC Trial | October 11, 2011 | Marketwire - Pharma and Biotech |
| Thallion Provides Update on Phase II SHIGATEC Trial | July 13, 2011 | Marketwire - Pharma and Biotech |
| Thallion commente l'éclosion d'E. coli en Europe | June 07, 2011 | Marketwire - Pharma and Biotech |
| Thallion Comments on European E. Coli Outbreak | June 06, 2011 | Marketwire - Pharma and Biotech |
| Thallion annonce le recrutement d'un premier patient dans la cohorte à dose élevée de son essai de Phase II SHIGATEC | May 30, 2011 | Marketwire - Pharma and Biotech |
| Thallion Announces First Patient Enrolled In High Dose Cohort of Phase II SHIGATEC Trial | May 30, 2011 | Marketwire - Pharma and Biotech |
| Thallion's Phase II SHIGATEC Trial Proceeds to High Dose Cohort | May 16, 2011 | Marketwire - Pharma and Biotech |
| Thallion poursuit l'essai de phase II SHIGATEC et commence la cohorte a dose élevée de Shigamabs(R) | May 16, 2011 | Marketwire - Pharma and Biotech |
| Les actionnaires de Thallion adoptent une résolution permettant à Thallion de mettre en place une offre publique de rachat dans le cours normal des activités | April 15, 2011 | Marketwire - Pharma and Biotech |
| Thallion Shareholders Adopt Special Resolution Enabling Thallion to Implement a Normal Course Issuer Bid | April 15, 2011 | Marketwire - Pharma and Biotech |
| Thallion Announces 2011 First Quarter Results; Completes First Cohort of Phase II SHIGATEC Trial | April 12, 2011 | Marketwire - Pharma and Biotech |
| Thallion annonce ses résultats pour le premier trimestre 2011; Complète la première cohorte de l'essai clinique de Phase II SHIGATEC | April 12, 2011 | Marketwire - Pharma and Biotech |
| Thallion annonce ses résultats pour l'exercice 2010 | February 24, 2011 | Marketwire - Pharma and Biotech |
| Thallion Announces 2010 Year End Results | February 24, 2011 | Marketwire - Pharma and Biotech |
| Thallion Pharmaceuticals Inc. and LFB Biotechnologies Initiate Phase II SHIGATEC Trial | November 29, 2010 | BioSpace - Breaking News |
| Thallion and LFB Initiate Phase II SHIGATEC Trial | November 29, 2010 | Marketwire - Pharma and Biotech |
| Thallion et LFB débutent l'essai de Phase II SHIGATEC | November 29, 2010 | Marketwire - Pharma and Biotech |
| Thallion Pharma Q3 revenue rises | October 13, 2010 | Pharmaceutical - Moreover |
| Thallion Announces 2010 Third Quarter Results | October 12, 2010 | Marketwire - Pharma and Biotech |
| Thallion annonce ses résultats pour le troisième trimestre 2010 | October 12, 2010 | Marketwire - Pharma and Biotech |
| Thallion annonce ses résultats pour le deuxième trimestre 2010 | July 12, 2010 | Marketwire - Pharma and Biotech |
| Thallion Announces 2010 Second Quarter Results | July 12, 2010 | Marketwire - Pharma and Biotech |
| Thallion Pharmaceuticals Inc. to Pay C$2.4 Million to Shorten Lease Obligation; to Cancel Remaining 6 Years of | June 24, 2010 | Biotechnology - Moreover |
| Thallion Pharmaceuticals Inc. to Pay C$2.4 Million to Shorten Lease Obligation; to Cancel Remaining 6 Years of 15-Year Lease | June 24, 2010 | BioSpace |
| Thallion Eliminates Long-Term Lease Obligation | June 24, 2010 | Marketwire - Pharma and Biotech |
| Thallion Pharmaceuticals Receives Arbitration Decision on TLN-232 License Agreement | June 16, 2010 | Marketwire - Pharma and Biotech |
| Thallion Announces 2010 First Quarter Results | April 12, 2010 | Marketwire - Pharma and Biotech |
| Thallion annonce ses résultats pour le premier trimestre 2010 | April 12, 2010 | Marketwire - Pharma and Biotech |
| Thallion annonce ses résultats pour l'exercice 2009 | February 23, 2010 | Marketwire - Pharma and Biotech |
| Thallion Announces 2009 Year End Results | February 23, 2010 | Marketwire - Pharma and Biotech |
| Avis d'appel conférence de Thallion Pharmaceutiques inc. résultats de l'exercice 2009 | February 19, 2010 | Marketwire - Pharma and Biotech |
| Notice of Thallion Pharmaceuticals Fiscal 2009 Year End Conference Call | February 19, 2010 | Marketwire - Pharma and Biotech |
| Thallion inks $130M licensing deal with LFB | February 16, 2010 | FierceBiotech |
| Thallion Pharmaceuticals Inc. and LFB Biotechnologies Sign Definitive Agreement to Develop and Commercialize Treatment for E. Coli (STEC) Infection; Eligible to Receive up to 95 Million Euros | February 16, 2010 | BioSpace |
| Thallion Pharmaceuticals and LFB Biotechnologies Sign Definitive Agreement to Develop and Commercialize Treatment for E. Coli (STEC) Infection | February 16, 2010 | Marketwire - Pharma and Biotech |
| Thallion Pharmaceutiques et LFB Biotechnologies signent une entente définitive visant le développement et la commercialisation d'un traitement contre les infections à E. coli (STEC) | February 16, 2010 | Marketwire - Pharma and Biotech |
| Thallion Announces Changes to Executive Management Structure and Board of Directors | January 11, 2010 | Marketwire - Pharma and Biotech |
| Thallion Pharmaceuticals Inc. Announces New CEO | January 11, 2010 | BioSpace |
| Thallion met un terme à son essai clinique évaluant TLN-4601 auprès de patients atteints d'un glioblastome multiforme suite à l'analyse des résultats intérimaires | December 18, 2009 | Marketwire - Pharma and Biotech |
| Thallion annonce la signature d'une lettre d'intention avec LFB Biotechnologies visant le développement et la commercialisation de Shigamabs(R) | December 18, 2009 | Marketwire - Pharma and Biotech |
| Thallion Discontinues Phase II Glioblastoma Multiforme Trial After Review of Interim Data | December 18, 2009 | Marketwire - Pharma and Biotech |
| Thallion Announces Letter of Intent With LFB Biotechnologies to Develop and Commercialize Shigamabs(R) | December 18, 2009 | Marketwire - Pharma and Biotech |
| Thallion Pharmaceuticals Inc. Discontinues Phase II Glioblastoma Multiforme Trial After Review of Interim Data | December 18, 2009 | BioSpace |
| Thallion reçoit 1,85 millions de dollars suite à la vente de son billet à ordre | December 17, 2009 | Marketwire - Pharma and Biotech |
| Thallion Receives $1.85 Million From Sale of Promissory Note | December 17, 2009 | Marketwire - Pharma and Biotech |
